November 25, 2017 –
A non-fasting test to measure low-density lipoprotein (LDL) cholesterol has many advantages for patients and physicians, but payers can also see some benefits, explained Eliot A. Brinton, MD, FAHA, FNLA, president of the Utah Lipid Center.
November 23, 2017 –
Diabetes prevention is about a change in lifestyle that will lead to internalized benefits that reduce risk, explained Paul Chew, MD, chief medical officer of Omada Health.
November 22, 2017 –
Real-world evidence isn't usually used for regulatory decisions, but the FDA is poised to start using it more, and there are challenges to using real-world data in clinical trials that will need to be navigated, said Nat Turner, co-founder and CEO of Flatiron Health.
November 14, 2017 –
As oncology moves toward more deep diagnostic testing and as standard of care continues to quickly evolve, technology advancements are necessary to continue to improve patient access to clinical trials, explained Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.
November 13, 2017 –
New approaches for measuring quality need to be developed to get frontline caregivers involved in the early stages of quality measure decisions, said Peter Aran, MD, medical director of population health management at Blue Cross Blue Shield of Oklahoma.
November 10, 2017 –
Aaron Lyss, director of value-based care for Tennessee Oncology, discusses the lessons thatís were learned after experiences with the Oncology Care Model.
November 08, 2017 –
Biosimilars for core therapeutics in cancer are starting to come out, and community oncologists need to understand what that means for their business, as well as what proposed policy changes could mean for reimbursement, explained Tesh Khullar,
November 03, 2017 –
With 30% to 40% of people in the workforce at risk for prediabetes, it is important for employers to embrace diabetes prevention in the workplace, said Paul Chew, MD, chief medical officer of Omada Health.
November 02, 2017 –
New Jersey is 1 of 3 states that will test a new set of metrics to assess how well new payment models have penetrated markets, explained Linda Schwimmer, JD, president and CEO of the New Jersey Health Care Quality Institute, which will lead the process in New Jersey.
October 31, 2017 –
Most practices are not ready to transition to the Medicare Access and CHIP Reauthorization Act (MACRA) payment models, although there is a leading group of practices that are more prepared to make the switch, said Aaron Lyss, director of value-based care for Tennessee Oncology.